Fundz

Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study

Apr 23, 2025

Contract Type

partnership

San FranciscoBiotechnologyHealth CareGeneticsTherapeutics

Description

Epicrispr Biotechnologies has announced a partnership with Springbok Analytics to incorporate advanced, AI-driven muscle MRI imaging and analysis into its first-in-human clinical trial of EPI-321, a potential first-in-class treatment for facioscapulohumeral muscular dystrophy (FSHD). The partnership aims to enhance early signal detection and inform the development of the therapy through Springbok's advanced MRI-based muscle analytics.

Company Information

Company

Epicrispr Biotechnologies

Location

San Francisco, California, United States

About

Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is entering the clinical stage to bring much-needed therapies to patients.

Related People

Alexandra
Senior decision-maker at this company
••••••••@••••••••

See Alexandra's verified email →

Daniel
Senior decision-maker at this company
••••••••@••••••••

See Daniel's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Epicrispr Biotechnologies's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Epicrispr Biotechnologies signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.